456 related articles for article (PubMed ID: 31671774)
1. Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target.
Aboubakar Nana F; Vanderputten M; Ocak S
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31671774
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.
Aboubakar Nana F; Lecocq M; Ladjemi MZ; Detry B; Dupasquier S; Feron O; Massion PP; Sibille Y; Pilette C; Ocak S
Mol Cancer Ther; 2019 Jan; 18(1):17-27. PubMed ID: 30352800
[TBL] [Abstract][Full Text] [Related]
3. DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway.
Ocak S; Yamashita H; Udyavar AR; Miller AN; Gonzalez AL; Zou Y; Jiang A; Yi Y; Shyr Y; Estrada L; Quaranta V; Massion PP
Oncogene; 2010 Dec; 29(48):6331-42. PubMed ID: 20802517
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab: A Review in Extensive-Stage SCLC.
Al-Salama ZT
Target Oncol; 2021 Nov; 16(6):857-864. PubMed ID: 34731446
[TBL] [Abstract][Full Text] [Related]
6. [Potential therapeutic implication of focal adhesion kinase in small-cell lung cancer].
Decouvreur C; Lecocq M; Pilette C; Aboubakar Nana F; Ocak S
Rev Mal Respir; 2023 Mar; 40(3):222-224. PubMed ID: 36828677
[TBL] [Abstract][Full Text] [Related]
7. Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect.
Zhang Y; Sun X
Onco Targets Ther; 2020; 13():10207-10220. PubMed ID: 33116602
[TBL] [Abstract][Full Text] [Related]
8. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L
J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
[TBL] [Abstract][Full Text] [Related]
10. A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Andrini E; Lamberti G; Mazzoni F; Riccardi F; Bonetti A; Follador A; Artioli F; Genova C; Barbieri F; Frassoldati A; Brighenti M; Colantonio I; Pasello G; Ficorella C; Cinieri S; Tiseo M; Gelsomino F; Tognetto M; Rihawi K; Ardizzoni A
Future Oncol; 2022 Mar; 18(7):771-779. PubMed ID: 35068173
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study.
Wang L; Lei X; Wang X
Comput Math Methods Med; 2022; 2022():2848220. PubMed ID: 35586668
[TBL] [Abstract][Full Text] [Related]
12. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
Behmoaram E; Bijian K; Jie S; Xu Y; Darnel A; Bismar TA; Alaoui-Jamali MA
Am J Pathol; 2008 Nov; 173(5):1540-50. PubMed ID: 18832579
[TBL] [Abstract][Full Text] [Related]
13. Focal adhesion kinase: Insight into its roles and therapeutic potential in oesophageal cancer.
Zhang Y; Liu S; Zhou S; Yu D; Gu J; Qin Q; Cheng Y; Sun X
Cancer Lett; 2021 Jan; 496():93-103. PubMed ID: 33038490
[TBL] [Abstract][Full Text] [Related]
14. Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.
Shirasawa M; Yoshida T; Shiraishi K; Takigami A; Takayanagi D; Imabayashi T; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yotsukura M; Yoshida Y; Nakagawa K; Tsuchida T; Hamamoto R; Yamamoto N; Motoi N; Kohno T; Watanabe SI; Ohe Y
Lung Cancer; 2023 May; 179():107183. PubMed ID: 37037178
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
Mathieu L; Shah S; Pai-Scherf L; Larkins E; Vallejo J; Li X; Rodriguez L; Mishra-Kalyani P; Goldberg KB; Kluetz PG; Theoret MR; Beaver JA; Pazdur R; Singh H
Oncologist; 2021 May; 26(5):433-438. PubMed ID: 33687763
[TBL] [Abstract][Full Text] [Related]
16. Expression of focal adhesion kinase in small-cell lung carcinoma.
Ocak S; Chen H; Callison C; Gonzalez AL; Massion PP
Cancer; 2012 Mar; 118(5):1293-301. PubMed ID: 21800286
[TBL] [Abstract][Full Text] [Related]
17. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ
Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332
[TBL] [Abstract][Full Text] [Related]
18. Focal adhesion kinase and its potential involvement in tumor invasion and metastasis.
Kornberg LJ
Head Neck; 1998 Dec; 20(8):745-52. PubMed ID: 9790298
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab: A Review in Extensive-Stage SCLC.
Frampton JE
Drugs; 2020 Oct; 80(15):1587-1594. PubMed ID: 32990939
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
